Reframing Hyaluronidase in Aesthetic Medicine: From “Dissolving Filler” to “Modifying Filler”

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for inducing weight loss has increased in recent years, resulting in a parallel reduction in demand for bariatric surgery. Consequently, the need for patients to undergo aesthetic procedures, including aesthetic breast surgery, following successful GLP-1 RA–induced weight loss is expected to increase while the demand created by postsurgical weight loss is expected to decrease. The objective of this narrative review is to examine the literature on the use of GLP-1 RAs and other mechanisms used for medical weight loss to assist plastic surgeons in achieving optimal aesthetic outcomes with breast surgery after weight loss occurs.

Recurrent herpes labialis (RHL) is a common condition characterized by episodic viral reactivation triggered by local or systemic factors. Hyaluronic acid (HA) lip augmentation is widely performed for aesthetic purposes, yet its potential association with changes in herpes labialis recurrence has not been systematically evaluated. The aim of this study was to investigate whether repeated lip augmentation with HA filler is associated with changes in the incidence of RHL episodes over time.

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting.

Minimally invasive filler injections are prevalent in aesthetic medicine. However, in recent years, the occurrence of complications has gradually increased.

Botulinum neurotoxins (eg, onabotulinumtoxinA) are used off-label to treat masseter muscle prominence (MMP), a benign enlargement of the masseter muscles that may be aesthetically undesirable.